FDA says shortage of breast biopsy needles expected to last until 2027
The Food and Drug Administration June 16 announced that a nationwide shortage of stereotactic breast biopsy needles is expected to last through the end of March 2027. The FDA said the shortage is due to a manufacturing disruption and that clinical management adjustments may be required for patients needing a breast biopsy. Healthcare providers are recommended to conserve their use of stereotactic breast biopsy needles. The agency said that Hologic issued a customer letter Jan. 2 that said all lots of its Brevera Breast Biopsy System Disposable 9 Gauge Needle were being removed due to a risk of metal and plastic particles being dislodged from the device during use.
Related News Articles
Headline
The Food and Drug Administration has issued an early alert for all automated Impella controllers by Abiomed following an issue that has caused three deaths and…
Headline
Boston Scientific, a large supplier of medical devices, said in an Aug. 26 statement posted on its website that on Aug. 25 it “identified a cybersecurity…
Headline
The Food and Drug Administration has issued early alerts for the following products: • Certain epidural kits by Medical Action…
Headline
The Food and Drug Administration has identified a Class I recall of certain Medline convenience kits containing B. Braun components that have Huons Bupivacaine…
Headline
The Food and Drug Administration Aug. 3 identified Class I recalls of two convenience kit products. Certain kits by Medline…
Headline
The Food and Drug Administration has identified Class I recalls of two products: certain Astral ventilators by Resmed due to a supercapacitor that may leak…